ANEB.US Anebulo Pharmaceuticals Inc

Healthcare Biotechnology USA Stocks
0.2800 USD
Close of Nov 14, 2026
0.0007 2.49
Market cap
USD 11.4M
P/E
-
P/B
0.01x
ROE
-104.8%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Dec 2025.

Is ANEB.US undervalued?

Graham number

The Graham number of Anebulo Pharmaceuticals Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Anebulo Pharmaceuticals Inc fundamental analysis

No fundamental analysis for Anebulo Pharmaceuticals Inc yet.

Anebulo Pharmaceuticals Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Anebulo Pharmaceuticals Inc

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States. The company's lead product candidate is the selonabant, a small-molecule antagonist of cannabinoid binding receptor type-1(CB1), which is in a phase II clinical trial to address the unmet medical need for a specific antidote for cannabis toxicit…

Full company profile